Alex Davis

Medical Oncologist & PhD candidate

[Genentech @genentech]

#Breaking: New positive Phase III results demonstrate superiority of an investigational molecule over standard-of-care KRAS G12C inhibitors in the first global head-to-head study in KRAS G12C-mutant non-small cell lung cancer: https://t.co/Bsxy2BeZ51

[Anirban Maitra @Aiims1742]

New compound from @RevMedicines RM-055 disclosed at #AACR26
They took a subtle finding 👉🏽Daraxonrasib-CYPA complex modestly increasing RAS GTP hydrolysis 👉🏽 to build a RAS GAP on steroids. RM-055 flattens Daraxonrasib resistant tumors including RAS amplified cases across models.

[Megan Sanders @MeganSa31833581]

Thank you to #MelMcLaughlin for speaking openly about her lung cancer, thankfully detected early & treated w surgery

Her story raises awareness of a widely misunderstood disease

Wishing Mel a smooth recovery & return on @Channel7 soon
https://t.co/PK6CPhGvuV
#LCSM #lungcancer

[Alex Davis @alexanderpdavis]

ESMO2025 DLL3 tour de force

[Stephen V Liu, MD @StephenVLiu]

Akeso reports Phase III HARMONi-A trial positive for survival. Ivonescimab (PD1/VEGF bispecific) + chemotherapy vs chemo in #EGFR NSCLC post TKI already showed PFS benefit (7.1m vs 4.8m) but OS was in question. Full results to be presented at #WCLC25.

https://t.co/6GAlMA2K0N

[Clinical Lung Cancer @ClinicalLung]

In a single-center study of NSCLC resections (2008-2020), long-term postop mortality dropped by almost 50% (HR 0.59; 95% CI 0.45–0.78) over 12 years, despite stable early post-op complications, possibly reflecting multiple contributing factors

Read more: https://t.co/61CqiEGWbZ

[Dr Deme Karikios @DKarikios]

What is the role of Common Sense Oncology in the Western Pacific? https://t.co/CYtTPnFVCl
@csoncol
#cancercare #cancer #commonsenseoncology

[Alex Davis @alexanderpdavis]

https://t.co/T23XdWbItd

Hello all! After a great TOGA ASM I'm running the City2Surf to raise funds for Thoracic Cancer research. Thanks for all your support.

[Jarushka Naidoo @DrJNaidoo]

💡Starting out in thoracic oncology?

The @IASLC Communications Committee proudly brings you:

‘50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic’

A whistlestop tour of key advances, distilled by global leaders
@JTOonline @OncoAlert #LCSM
https://t.co/aRjpaDYAbk

[Stephen Parnis @SParnis]

I loved watching "ER" when I was a resident. But I can't watch "The Pitt". It's too close to home. I take the care of self & colleagues much more seriously these days.
https://t.co/EoM2aCst87

[Alex Davis @alexanderpdavis]

@Mal_Itchins Great day!

[Dr Andrew Parsonson @AOParsonson]

Grateful for the opportunity to present DB-1311/BNT324 (a novel B7H3 ADC) a Ph 1/2 study in patients with heavily pretreated CRPC (Abstract #5015) at #ASCO25 🎤 @Macquarie_Uni investigators: John Park @DSabanathan @HowardGurney @AlisonZhangMBBS Wei Yen Chan 🧵 1/7

[Alex Davis @alexanderpdavis]

Very comprehensive overview of where EGFR mutant lung cancer treatment is at.

[NatureRevClinOncol @NatRevClinOncol]

In a Review now published online, Fei Zhou, Haoyue Guo, Yang Xia, Xiuning Le, Daniel Tan, Suresh Ramalingam & Caicun Zhou provide a comprehensive overview of the treatment landscape for EGFR-mutant non-small-cell #lungcancer https://t.co/W7nT6149Za

[Prunella Blinman @drprunellab]

Disheartening.
Frustrating.
Devastating.

Patients unable to access immunotherapy via PBS for recurrent NSCLC due to once in a lifetime rule that is inconsistent w/ current standard of care.

Communicating this to patients is hard.

@MOGA_ORG pls keep advocating for change 🙏

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Check out this recent proof-of-concept study looking at detection of #AntibodyDrugConjugate-induced interstitial lung disease using circulating cell-free DNA led by @AlbertGrinshpun and colleagues.
🔓https://t.co/rVcksOtwlx

✍️@AlbertGrinshpun @PTarantinoMD @stolaney1
@orifridlich @ESMO_Open

[Alex Davis @alexanderpdavis]

Sydney Swans in Grand Finals have strong Washington Generals vibes

[Alex Davis @alexanderpdavis]

@omalirp @MandersPeter As is tradition

[Alex Davis @alexanderpdavis]

@omalirp @myESMO Enjoy the lounge

[Patrick Forde @FordePatrick]

Surprising results, stereotactic radiation plus anti-PD1 for stage 1-2 NSCLC, addition of immunotherapy does not confer benefit #lcsm https://t.co/YrERyeBAco

[Alex Davis @alexanderpdavis]

Great discussion on drug reimbursement in Australia and particularly in thoracic oncology.

[Thoracic Oncology Group of Australasia @TOGAANZ]

🎙️ NEW PODCAST: Access to New Medicines: Which Surrogate Endpoints Matter?

Listen on Apple https://t.co/BXBiXqGSZh
Listen on Spotify https://t.co/6J6QQ7mfT4